Entering text into the input field will update the search result below

Auris Medical updates clinical development plan for inner ear hearing loss drug candidate

May 04, 2015 11:35 AM ETAltamira Therapeutics Ltd. (CYTO) StockCYTOBy: Douglas W. House, SA News Editor
  • Auris Medical's (EARS +0.9%) development plan for Orphan Drug-designated AM-111 includes two pivotal clinical trials in idiopathic (cause unknown) sudden sensorineural hearing loss ((ISSNHL)), which is the most frequent type of acute sensorineural hearing loss (ASNHL).
  • The first trial, called HELIOS, will commence in Q3 and will enroll ~255 patients in Europe and Asia. The second trial, called ASSENT, will be based in the U.S. and commence enrollment in Q1 2016. Both groups will receive a single dose of AM-111 (either 0.4 mg/Ml or 0.8 mg/mL) or placebo. The number of subjects will be comparable with HELIOS. Patients in ASSENT may receive a course of oral corticosteroids as background therapy.
  • The company is preparing a third Phase 2 trial, called REACH, that should commence in Q3 2016. In this study, patients with residual hearing who are undergoing cochlear implant surgery will receive AM-111 intraoperatively.
  • AM-111 is a biodegradable gel that is administered in a single dose intratympanic injection into the middle ear. From there, the drug diffuses through the round window membrane into the cochlea. Its active ingredient is a synthetic peptide that inhibits the JNK stress kinase coupled to an intracellular transporter.
  • In animal models of cochlear stress, AM-111's protective effects have been demonstrated in acute acoustic trauma, acute labyrinthitis, drug ototoxicity, bacterial infection, cochlear ischemia and cochlear implant trauma.

Recommended For You

More Trending News

About CYTO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CYTO--
Altamira Therapeutics Ltd.